Safeguards for Using Viral Vector Systems in Human Gene Therapy: A Resource for Biosafety Professionals Mitigating Risks in Health Care Settings.
Alex M BrownJill BlindKatie CampbellSumit GhoshPublished in: Applied biosafety : journal of the American Biological Safety Association (2020)
With continuing advances in the field of gene therapy, the oversight structure needs to evolve for the health care setting. To deliver the best outcomes to the patients of these therapies, researchers, Institutional Biosafety Committees, and health care workers need to collaborate on training programs to safeguard the public trust in the use of this technology both in clinical trials and as FDA-approved therapeutics.
Keyphrases
- gene therapy
- healthcare
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- sars cov
- small molecule
- public health
- mental health
- health information
- adipose tissue
- risk assessment
- patient reported outcomes
- induced pluripotent stem cells
- type diabetes
- human health
- insulin resistance
- skeletal muscle
- affordable care act
- health insurance
- virtual reality
- glycemic control